{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:36:29Z","timestamp":1780637789877,"version":"3.54.1"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["52273251"],"award-info":[{"award-number":["52273251"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["52473264"],"award-info":[{"award-number":["52473264"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["52233007"],"award-info":[{"award-number":["52233007"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Colloid and Interface Science"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jcis.2025.138144","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T11:05:24Z","timestamp":1749467124000},"page":"138144","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"P1","title":["In situ generation of anti-leukemia vaccine by immunogenic dual-drug nanomedicine and polymersomal CpG nanoadjuvant"],"prefix":"10.1016","volume":"699","author":[{"given":"Lanlan","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhen","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhai","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6287-1555","authenticated-orcid":false,"given":"Huanli","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyuan","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcis.2025.138144_b0005","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","article-title":"Acute myeloid leukaemia","volume":"401","author":"DiNardo","year":"2023","journal-title":"Lancet"},{"issue":"2025","key":"10.1016\/j.jcis.2025.138144_b0010","first-page":"46","article-title":"Acute myeloid leukemia management and research in 2025","volume":"75","author":"Kantarjian","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.jcis.2025.138144_b0015","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/d41573-019-00142-4","article-title":"The acute myeloid leukaemia market","volume":"19","author":"Schaefer","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jcis.2025.138144_b0020","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41571-021-00509-w","article-title":"Towards precision medicine for AML","volume":"18","author":"D\u00f6hner","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jcis.2025.138144_b0025","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/s41551-020-00624-6","article-title":"Therapeutic vaccination against leukaemia via the sustained release of co-encapsulated anti-PD-1 and a leukaemia-associated antigen","volume":"5","author":"Xie","year":"2021","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.jcis.2025.138144_b0030","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13045-023-01424-6","article-title":"Recent advances in targeted therapies in acute myeloid leukemia","volume":"16","author":"Bhansali","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jcis.2025.138144_b0035","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1038\/s41591-024-03271-5","article-title":"Cytokine-mediated CAR t therapy resistance in AML","volume":"30","author":"Bhagwat","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.jcis.2025.138144_b0040","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13045-022-01247-x","article-title":"Cancer vaccines as promising immuno-therapeutics: Platforms and current progress","volume":"15","author":"Liu","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jcis.2025.138144_b0045","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic cancer vaccines","volume":"21","author":"Saxena","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jcis.2025.138144_b0050","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1016\/j.cell.2022.06.035","article-title":"Cancer vaccines: Building a bridge over troubled waters","volume":"185","author":"Sellars","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.jcis.2025.138144_b0055","doi-asserted-by":"crossref","first-page":"4057","DOI":"10.1021\/acs.chemmater.1c00629","article-title":"Vaccine nanoparticles derived from mung beans for cancer immunotherapy","volume":"33","author":"Wang","year":"2021","journal-title":"Chem. Mater."},{"key":"10.1016\/j.jcis.2025.138144_b0060","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202303080","article-title":"A personalized cancer vaccine that induces synergistic innate and adaptive immune responses","volume":"35","author":"Kuen","year":"2023","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jcis.2025.138144_b0065","article-title":"Systemic multifunctional nanovaccines for potent personalized immunotherapy of acute myeloid leukemia","volume":"36","author":"Zhang","year":"2024","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jcis.2025.138144_b0070","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41577-023-00937-y","article-title":"Challenges in developing personalized neoantigen cancer vaccines","volume":"24","author":"Katsikis","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jcis.2025.138144_b0075","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41392-023-01674-3","article-title":"Therapeutic cancer vaccines: Advancements, challenges and prospects","volume":"8","author":"Fan","year":"2023","journal-title":"Sig. Transduct. Target. Ther."},{"key":"10.1016\/j.jcis.2025.138144_b0080","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/s41573-024-00974-9","article-title":"Enhancing in situ cancer vaccines using delivery technologies","volume":"23","author":"Gong","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jcis.2025.138144_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2024.102286","article-title":"Nanotechnology-based in situ cancer vaccines: Mechanisms, design, and recent advances","volume":"56","author":"Niu","year":"2024","journal-title":"Nano Today"},{"key":"10.1016\/j.jcis.2025.138144_b0090","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat. Rev. Immunol"},{"key":"10.1016\/j.jcis.2025.138144_b0095","article-title":"Immunogenic cell death activates the tumor immune microenvironment to boost the immunotherapy efficiency","volume":"9","author":"Li","year":"2022","journal-title":"Adv. Sci."},{"key":"10.1016\/j.jcis.2025.138144_b0100","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.semcdb.2023.10.007","article-title":"Immunogenic cell stress and death in the treatment of cancer","volume":"156","author":"Pan","year":"2024","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.jcis.2025.138144_b0105","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1038\/s41467-020-19540-z","article-title":"Biomaterial-based scaffold for in situ chemo-immunotherapy to treat poorly immunogenic tumors","volume":"11","author":"Wang","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jcis.2025.138144_b0110","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41590-022-01132-2","article-title":"Immunogenic cell stress and death","volume":"23","author":"Kroemer","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jcis.2025.138144_b0115","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12967-023-04017-6","article-title":"Immunogenic cell death in cancer: Concept and therapeutic implications","volume":"21","author":"Galluzzi","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.jcis.2025.138144_b0120","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.jcis.2025.02.179","article-title":"A stimuli\u2013responsive immunostimulant to activate chemo-immunotherapeutic effects by inducing DNA damage and sting activation","volume":"688","author":"Zhang","year":"2025","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.jcis.2025.138144_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.103905","article-title":"Nanomedicines as enhancers of tumor immunogenicity to augment cancer immunotherapy","volume":"29","author":"Dogheim","year":"2024","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.jcis.2025.138144_b0130","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1016\/j.apsb.2024.03.022","article-title":"Engineering nanomedicines for immunogenic eradication of cancer cells: Recent trends and synergistic approaches","volume":"14","author":"Elzoghby","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jcis.2025.138144_b0135","first-page":"486","article-title":"Nanomedicine to aid immunogenic cell death (ICD)-based anticancer therapy, Trends","volume":"10","author":"Demuynck","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.jcis.2025.138144_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122064","article-title":"Self-immolative polymer-based immunogenic cell death inducer for regulation of redox homeostasis","volume":"295","author":"Jeon","year":"2023","journal-title":"Biomaterials"},{"key":"10.1016\/j.jcis.2025.138144_b0145","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1158\/1535-7163.MCT-15-0897","article-title":"Plk1 inhibitors in cancer therapy: From laboratory to clinics","volume":"15","author":"Gutteridge","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jcis.2025.138144_b0150","doi-asserted-by":"crossref","first-page":"10133","DOI":"10.1021\/acs.jmedchem.2c00614","article-title":"Polo-like kinase 1 inhibitors in human cancer therapy: Development and therapeutic potential","volume":"65","author":"Zhang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jcis.2025.138144_b0155","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1039\/D2CS00647B","article-title":"Materials engineering strategies for cancer vaccine adjuvant development","volume":"52","author":"Zhang","year":"2023","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.jcis.2025.138144_b0160","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41573-021-00163-y","article-title":"Emerging concepts in the science of vaccine adjuvants","volume":"20","author":"Pulendran","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jcis.2025.138144_b0165","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.addr.2008.12.008","article-title":"Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists","volume":"61","author":"Vollmer","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jcis.2025.138144_b0170","first-page":"61","article-title":"Co-delivery of gemcitabine and paclitaxel plus NanoCpG empowers chemoimmunotherapy of postoperative \u201ccold\u201d triple-negative breast cancer","volume":"25","author":"Guo","year":"2023","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.jcis.2025.138144_b0175","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202007787","article-title":"Daratumumab immunopolymersome-enabled safe and CD38-targeted chemotherapy and depletion of multiple myeloma","volume":"33","author":"Yu","year":"2021","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jcis.2025.138144_b0180","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1021\/acs.biomac.8b01243","article-title":"Smart polymersomes dually functionalized with cRGD and fusogenic GALA peptides enable specific and high-efficiency cytosolic delivery of apoptotic proteins","volume":"20","author":"Yao","year":"2019","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jcis.2025.138144_b0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.actbio.2025.05.041","article-title":"Vincristine\/volasertib polymersome injection enables high-efficiency synergistic treatment of acute lymphoblastic leukemia","author":"Deng","year":"2025","journal-title":"Acta Biomater."},{"key":"10.1016\/j.jcis.2025.138144_b0190","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202202400","article-title":"Advances in lipid-based codelivery systems for cancer and inflammatory diseases","volume":"12","author":"Jogdeo","year":"2023","journal-title":"Adv. Healthcare Mater."},{"key":"10.1016\/j.jcis.2025.138144_b0195","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s41565-022-01310-1","article-title":"Molecular bottlebrush prodrugs as mono- and triplex combination therapies for multiple myeloma","volume":"18","author":"Detappe","year":"2023","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jcis.2025.138144_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2023.101872","article-title":"Exogenous CD38 upregulation enables high-efficacy dually cascade targeted molecular therapy of leukemia","volume":"50","author":"Du","year":"2023","journal-title":"Nano Today"},{"key":"10.1016\/j.jcis.2025.138144_b0205","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202209984","article-title":"Exogenous antigen upregulation empowers antibody targeted nanochemotherapy of leukemia","volume":"35","author":"Yue","year":"2023","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jcis.2025.138144_b0210","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.actbio.2020.06.020","article-title":"GE11 peptide-installed chimaeric polymersomes tailor-made for high-efficiency EGFR-targeted protein therapy of orthotopic hepatocellular carcinoma","volume":"113","author":"Zhou","year":"2020","journal-title":"Acta Biomaterialia"},{"key":"10.1016\/j.jcis.2025.138144_b0215","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10495-018-1508-1","article-title":"Clotam enhances anti-proliferative effect of vincristine in ewing sarcoma cells","volume":"24","author":"Shelake","year":"2019","journal-title":"Apoptosis"},{"key":"10.1016\/j.jcis.2025.138144_b0220","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/med.21392","article-title":"Spotlight on volasertib: Preclinical and clinical evaluation of a promising plk1 inhibitor","volume":"36","author":"Van den Bossche","year":"2016","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.jcis.2025.138144_b0225","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.7150\/ijms.60135","article-title":"PLK1 inhibition induces immunogenic cell death and enhances immunity against NSCLC","volume":"18","author":"Zhou","year":"2021","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.jcis.2025.138144_b0230","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202103689","article-title":"Immunotherapy of malignant glioma by noninvasive administration of TLR9 agonist CpG nano-immunoadjuvant","volume":"9","author":"Wei","year":"2022","journal-title":"Adv. Sci."},{"key":"10.1016\/j.jcis.2025.138144_b0235","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.actbio.2022.03.030","article-title":"Glycyrrhetinic acid nanoparticles combined with ferrotherapy for improved cancer immunotherapy","volume":"144","author":"Li","year":"2022","journal-title":"Acta Biomater."},{"key":"10.1016\/j.jcis.2025.138144_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2020.126891","article-title":"CXCR4 and CD44 dual-targeted prussian blue nanosystem with daunorubicin loaded for acute myeloid leukemia therapy","volume":"405","author":"Bai","year":"2021","journal-title":"Chem. Eng. J."},{"key":"10.1016\/j.jcis.2025.138144_b0245","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.actbio.2022.11.007","article-title":"Amplifying sting activation by bioinspired nanomedicine for targeted chemo- and immunotherapy of acute myeloid leukemia","volume":"157","author":"Wang","year":"2023","journal-title":"Acta Biomater."},{"key":"10.1016\/j.jcis.2025.138144_b0250","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.immuni.2022.04.016","article-title":"Dendritic cells can prime anti-tumor CD8+ T cell responses through major histocompatibility complex cross-dressing","volume":"55","author":"MacNabb","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.jcis.2025.138144_b0255","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1016\/j.immuni.2023.08.014","article-title":"Dendritic cells as shepherds of T cell immunity in cancer","volume":"56","author":"Pittet","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.jcis.2025.138144_b0260","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1186\/s12951-022-01491-w","article-title":"Biomimetic doxorubicin\/ginsenoside co-loading nanosystem for chemoimmunotherapy of acute myeloid leukemia","volume":"20","author":"Chen","year":"2022","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.jcis.2025.138144_b0265","doi-asserted-by":"crossref","first-page":"466","DOI":"10.3390\/pharmaceutics14020466","article-title":"Hyaluronic acid nanoparticles for immunogenic chemotherapy of leukemia and t-cell lymphoma","volume":"14","author":"Krishnan","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jcis.2025.138144_b0270","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/bjh.15818","article-title":"Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell\/AML vaccine","volume":"185","author":"Nahas","year":"2019","journal-title":"Br. J. Haematol."}],"container-title":["Journal of Colloid and Interface Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021979725015358?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021979725015358?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T01:19:03Z","timestamp":1769649543000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021979725015358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":54,"alternative-id":["S0021979725015358"],"URL":"https:\/\/doi.org\/10.1016\/j.jcis.2025.138144","relation":{},"ISSN":["0021-9797"],"issn-type":[{"value":"0021-9797","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In situ generation of anti-leukemia vaccine by immunogenic dual-drug nanomedicine and polymersomal CpG nanoadjuvant","name":"articletitle","label":"Article Title"},{"value":"Journal of Colloid and Interface Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcis.2025.138144","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"138144"}}